Skip to main content

Advertisement

Table 1 Summary of patient baseline characteristics a

From: Modulation of β-amyloid by a single dose of GSK933776 in patients with mild Alzheimer’s disease: a phase I study

   GSK933776 dose
Demographic characteristics Sex 1 mg/kg (n = 6) 3 mg/kg (n = 6) 6 mg/kg (n = 6)
Mean age (yr) (range)   69.0 (61 to 79) 68.3 (57 to 79) 66.0 (58 to 77)
Sex, n (%) Female 2 (33) 5 (83) 3 (50)
  Male 4 (67) 1 (17) 3 (50)
Race, n (%) Caucasian 6 (100) 6 (100) 6 (100)
Mean BMI kg/m2 (range)   23.7 (20 to 26) 23.5 (21 to 28) 25.4 (22 to 27)
APOE ϵ4 status, n (%) E2E3 0 (0) 0 (0) 0 (0)
  E3E3 1 (17) 0 (0) 0 (0)
  E3E4 3 (50) 2 (40)/1b 3 (75)c
  E4E4 2 (33) 3 (60) 1 (25)
  1. aBMI: Body mass index. bOne participant who entered the study and provided pharmacogenetics (PGx) consent and a sample in the 1 mg/kg dosing arm reentered the study in the 3 mg/kg dosing arm. The PGx consent and sample were obtained again unnecessarily for the 3 mg/kg dosing. The second PGx sample was subsequently destroyed to maintain consistency within the study by collecting and using only one sample per individual. cTwo participants who had entered the study and provided PGx consent and a sample in the 3 mg/kg dosing arm reentered the study in the 6 mg/kg dosing arm. The PGx consent and sample were not obtained again for these patients.